<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> (LAC) consist of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo>, detected via their <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> properties in vitro </plain></SENT>
<SENT sid="1" pm="."><plain>Strong LAC relate to <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo>, a hallmark of the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We have analyzed whether detection of this syndrome would benefit from thrombin generation measurements </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, calibrated automated thrombography was done in <z:mpath ids='MPATH_458'>normal</z:mpath> plasma (n = 30) and LAC patient plasma (n = 48 non-anticoagulated, n = 12 on oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi>), diluted 1:1 with a <z:mpath ids='MPATH_458'>normal</z:mpath> plasma pool </plain></SENT>
<SENT sid="4" pm="."><plain>The anti-beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I monoclonal antibody 23H9, with known LAC properties, delayed the lag time and reduced the peak height during thrombin generation induction in <z:mpath ids='MPATH_458'>normal</z:mpath> plasma dose-dependently (0-150 microg/ml) </plain></SENT>
<SENT sid="5" pm="."><plain>At variance, LAC patient 1:1 plasma mixtures manifested variable lag time prolongations and/or peak height reductions </plain></SENT>
<SENT sid="6" pm="."><plain>Coupling these two most informative thrombin generation parameters in a peak height/lag time ratio, and upon normalization versus the <z:mpath ids='MPATH_458'>normal</z:mpath> plasma pool, this ratio distributed normally and was reduced in the plasma mixtures, for 59/60 known LAC plasmas </plain></SENT>
<SENT sid="7" pm="."><plain>The normalized peak height/lag time ratio correlated well with the normalized dilute prothrombin time, diluted Russell's viper venom time and <z:chebi fb="48" ids="30563">silica</z:chebi> clotting time, measured in 1:1 plasma mixtures (correlation coefficients 0.59-0.72) </plain></SENT>
<SENT sid="8" pm="."><plain>The <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> effects of activated protein C (0-7.5 nM) or 23H9 (0-150 microg/ml), spiked in the 1:1 LAC plasma mixtures were reduced for the majority of patients, compatible with functional competition between patient LAC and activated protein C and LAC and 23H9, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>Hence, the normalized thrombin generation-derived peak height/lag time ratio identifies LAC in plasma with high sensitivity in a single assay, irrespective of the patient's treatment with oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> </plain></SENT>
</text></document>